Physician profile
Terrell Phillips
NPI 1871534024
$30,519.24
in general payments reported to CMS, 2019-2025
49 companies · $512 in 2025
The $512 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $1,557 · 2021: $2,021 · 2022: $3,528 · 2023: $1,474 · 2024: $487 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20,074.09 | 2019-2025 | Relistor |
| Abbott Laboratories | $2,801.21 | 2019-2025 | Proclaim, Eterna |
| Relievant Medsystems, INC. | $802.04 | 2021-2023 | Intracept |
| Stratus Medical, LLC | $796.37 | 2020-2023 | Nimbus |
| Genesys Orthopedics Systems, L.L.C. | $620.15 | 2022 | |
| Avanos Medical | $602.01 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $584.05 | 2019-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $385.89 | 2020-2024 | Intracept, Wavewriter Alpha Prime 16 |
| Grt US Holding, INC. | $334.48 | 2021-2022 | |
| Pfizer INC. | $298.36 | 2019 | |
| Forte Bio-Pharma LLC | $271.01 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Astrazeneca Pharmaceuticals Lp | $219.65 | 2019-2020 | |
| Daiichi Sankyo INC. | $197.79 | 2019 | |
| Vertos Medical, INC. | $195.44 | 2022-2023 | Mild Device Kit |
| Medtronic, INC. | $176.32 | 2022-2024 | Intellis Adaptivestim |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrell Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.